IP Library Granted Patent US 9,771,563
Granted Patent B2
US 9,771,563 · App. 15/179,657 · Granted Sep 26, 2017

Chemical approaches for generation of induced pluripotent stem cells

Inventors: Yan Shi (Beijing, CN); Caroline Desponts (La Jolla, CA); Tongxiang Lin (San Diego, CA); Wenlin Li (Shanghai, CN); Saiyong Zhu (San Francisco, CA); Sheng Ding (Orinda, CA)
Assignee: The Scripps Research Institute
C12N5/0696C12N15/85C12N2500/14C12N2501/01C12N2501/065C12N2501/15C12N2501/602C12N2501/603C12N2501/604C12N2501/605C12N2501/608C12N2501/727C12N2506/08C12N2506/094C12N2506/1307C12N2506/28C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,771,563
App. No.
15/179,657
Granted
Sep 26, 2017
Kind
B2
Abstract

The present invention provides for identification and use of small molecules to induce pluripotency in mammalian cells as well as other methods of inducing pluripotency.

Claims (14)

1. A composition comprising:

(i) a mammalian non-pluripotent cell comprising exogenous polynucleotides comprising an Oct4 encoding polynucleotide and a Klf encoding polynucleotide; and

(ii) a small molecule composition comprising a GSK-3 inhibitor.

2. The composition of claim 1 , wherein the small molecule composition further comprises a MEK inhibitor, an Erk inhibitor, or a TGFβ receptor/ALK5 inhibitor.

3. The composition of claim 2 , wherein the TGFβ receptor/ALK5 inhibitor is selected from the group consisting of: A-83-01 and SB431542.

4. The composition of claim 2 , wherein the MEK inhibitor is PD0325901.

5. The composition of claim 1 , wherein the GSK-3 inhibitor is selected from the group consisting of: CHIR99021, CHIR98014, and 6-bromoindirubin-3′-oxime (BIO).

6. The composition of 1 , wherein the mammalian non-pluripotent cell is contacted with exogenous polynucleotides comprising an Oct4 encoding polynucleotide and a Klf4 encoding polynucleotide to initiate reprogramming.

7. A composition comprising: an induced pluripotent stem cell reprogrammed from a mammalian non-pluripotent cell, and a small molecule composition comprising a GSK-3 inhibitor.

8. The composition of claim 7 , wherein the small molecule composition further comprises a MEK inhibitor, an Erk inhibitor, or a TGFβ receptor/ALK5 inhibitor.

9. The composition of claim 8 , wherein the TGFβ receptor/ALK5 inhibitor is selected from the group consisting of: A-83-01 and SB431542.

10. The composition of claim 8 , wherein the MEK inhibitor is PD0325901.

11. The composition of claim 7 , wherein the GSK-3 inhibitor is selected from the group consisting of: CHIR99021, CHIR98014, and 6-bromoindirubin-3′-oxime (BIO).

12. The composition of claim 8 , wherein the induced pluripotent stem cell is reprogrammed by introducing into mammalian non-pluripotent cell exogenous polynucleotides comprising an Oct4 encoding polynucleotide and a Klf encoding polynucleotide to initiate reprogramming.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2017
From: SHI, YAN; DESPONTS, CAROLINE; LIN, TONGXIANG; LI, WENLIN; ZHU, SAIYONG; DING, SHENG
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 042711/0960 →
Continuity (5)
Continuation 12753386 · Apr 2, 2010
Continuation In Part PCTUS2009037429 · Mar 17, 2009
Provisional Application 61069956 · Mar 17, 2008
Provisional Application 61197986 · Oct 31, 2008
Related Publication 20160369244A1 · Dec 22, 2016